Intravenous versus Subcutaneous Immunoglobulin in Primary Immunodeficiency: Real-World Evaluation of Safety, Efficacy, and Patient Perceptions
Background: Patients with primary immunodeficiency disorders (PIDD) typically require life-long immunoglobulin

